TY - JOUR
T1 - Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome
AU - Rosenfeld, Ron G.
AU - Hintz, Raymond L.
AU - Johanson, Ann J.
AU - Sherman, Barry
AU - Brasel, Jo Anne
AU - Burstein, Stephen
AU - Chernausek, Steven
AU - Compton, Peter
AU - Frane, James
AU - Gotlin, Ronald W.
AU - Kuntze, Joyce
AU - Lippe, Barbara M.
AU - Mahoney, Patrick C.
AU - Moore, Wayne V.
AU - New, Maria I.
AU - Saenger, Paul
AU - Sybert, Virginia
PY - 1988/8
Y1 - 1988/8
N2 - Seventy girls with Turner syndrome, 4 to 12 years of age, participated in a prospective, randomized study to determine the effects on growth of methionyl human growth hormone (met-hGH) or oxandrolone. Subjects were randomly assigned to receive either no treatment (control) or met-hGH (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination met-hGH plus oxandrolone. At the end of an initial period of 12 to 20 months, patients in the original control and oxandrolone groups were given combination met-hGH plus oxandrolone. At that time the dosage of oxandrolone was lowered to 0.0625 mg/kg/day. Sixty-five subjects have now completed the first 3 years of the study. Compared with the control growth rate for year 1 (3.8 cm/yr), significant increases in growth rate were seen in all 3 years of combination therapy (9.8, 7.4, and 6.1 cm/yr, respectively) and in the first 2 years of treatment with met-hGH alone (6.6, 5.4, and 4.6 cm/yr). When growth velocity was expressed as standard deviation for age in girls with Turner syndrome, significant increases relative to the control group for year 1(-0.1 SD) were seen in all three years of both combination therapy and met-hGH alone (combination, +6.6, +4.3, +3.0 SD; met-hGH, +3.1, +2.0, +1.4 SD). After 3 years of treatment, predicted adult height by the method of Bayley-Pinneau increased 4.5 cm in the met-hGH group and 8.2 cm in the combination group.
AB - Seventy girls with Turner syndrome, 4 to 12 years of age, participated in a prospective, randomized study to determine the effects on growth of methionyl human growth hormone (met-hGH) or oxandrolone. Subjects were randomly assigned to receive either no treatment (control) or met-hGH (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination met-hGH plus oxandrolone. At the end of an initial period of 12 to 20 months, patients in the original control and oxandrolone groups were given combination met-hGH plus oxandrolone. At that time the dosage of oxandrolone was lowered to 0.0625 mg/kg/day. Sixty-five subjects have now completed the first 3 years of the study. Compared with the control growth rate for year 1 (3.8 cm/yr), significant increases in growth rate were seen in all 3 years of combination therapy (9.8, 7.4, and 6.1 cm/yr, respectively) and in the first 2 years of treatment with met-hGH alone (6.6, 5.4, and 4.6 cm/yr). When growth velocity was expressed as standard deviation for age in girls with Turner syndrome, significant increases relative to the control group for year 1(-0.1 SD) were seen in all three years of both combination therapy and met-hGH alone (combination, +6.6, +4.3, +3.0 SD; met-hGH, +3.1, +2.0, +1.4 SD). After 3 years of treatment, predicted adult height by the method of Bayley-Pinneau increased 4.5 cm in the met-hGH group and 8.2 cm in the combination group.
UR - http://www.scopus.com/inward/record.url?scp=0023764332&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(88)80290-7
DO - 10.1016/S0022-3476(88)80290-7
M3 - Article
C2 - 3397807
AN - SCOPUS:0023764332
SN - 0022-3476
VL - 113
SP - 393
EP - 400
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 2
ER -